Results 21 to 30 of about 136,614 (358)

Kan vericilerde HBsAg, anti-HCV, anti-HIV ve Sifilis seroprevalansı

Sakarya Tıp Dergisi, 2011
Bu çalışmada Afyon Kocatepe Üniversitesi Tıp Fakültesi Kan Merkezi'ne başvuran donörlerde HBsAg, anti-HCV, anti-HIV 1/2 ve RPR seroprevalansının tespiti ve oranların yıllara ve cinsiyete göre dağılımının belirlenmesi amaçlanmıştır.
Mustafa Altındiş, Raike Kalaycı, Savaş Aslan   +2 more
doaj   +1 more source

The prevalence of viral hepatitis D in the world

Эпидемиология и вакцинопрофилактика, 2022
Relevance According to many researchers, hepatitis D worsens the prognosis of hepatitis B in 80–90% of cases, accelerating fibrosis and leading to liver cirrhosis or hepatocellular carcinoma. Aims. To present a review of data on prevalence of hepatitis D
V. G. Akimkin, Z. B. Ponezheva, Kh. G. Omarova, Yu. А. Goloverova, S. V. Ugleva, S. V. Shabalina   +5 more
doaj   +1 more source

Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis.

Gastroenterology, 2019
BACKGROUND & AIMS Seroclearance of hepatitis B surface antigen (HBsAg) is a marker for clearance of chronic hepatitis B virus (HBV) infection, but reported annual incidence rates of HBsAg seroclearance vary.
Y. Yeo, H. Ho, Hwai I. Yang, T. Tseng, T. Hosaka, H. Trinh, Min-Sun Kwak, Young Min Park, J. Fung, M. Buti, Manuel Rodríguez, S. Treeprasertsuk, C. Preda, T. Ungtrakul, P. Charatcharoenwitthaya, Xiangyong Li, Jiayi Li, Jian Q. Zhang, M. Le, Bin Wei, B. Zou, A. Le, Donghak Jeong, Nicholas Chien, Leslie Y. Kam, Chiao-Chin Lee, M. Riveiro‐Barciela, D. Istratescu, T. Sriprayoon, Y. Chong, T. Tanwandee, M. Kobayashi, F. Suzuki, M. Yuen, Hyo‐suk Lee, J. Kao, A. Lok, Chun-Ying Wu, M. Nguyen   +38 more
semanticscholar   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis [PDF]

, 2019
Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ...
Altieri, Marta, Annecca, Rosanna, Aragri, Marianna, Ciardi, Maria R, Iannetta, Marco, Mastroianni, Claudio M, Pontecorvo, Simona, Russo, Gianluca, Salpini, Romina, Svicher, Valentina, Vullo, Vincenzo, Zingaropoli, Maria A   +11 more
core   +1 more source

Prevalence of Hepatitis B and Hepatitis C in patients undergoing hemodialysis at a teaching hospital in Uttarakhand

Journal of Family Medicine and Primary Care, 2022
Introduction: Hemodialysis (HD) requires blood exposure to infectious materials through the extracorporeal circulation for a prolonged period, and exposure to risk factors for nosocomial infections is always there.
Dimple Raina, Neha Rawat, Ajay K Pandita
doaj   +1 more source

An expert consensus for the management of chronic hepatitis B in Asian Americans. [PDF]

, 2018
BACKGROUND: Hepatitis B virus (HBV) infection is common with major clinical consequences. In Asian Americans, the HBsAg carrier rate ranges from 2% to 16% which approximates the rates from their countries of origin.
Abbas, Abbas, Ahn, Beasley, Beasley, Bisceglie, Bogr, Brown, Buti, Centers for Disease Control, Chae, Chan, Chang, Chang, Chang, Chang, Chang, Chao, Chaung, Chen, Chen, Chen, Chen, Chi, Chien, Choe, Chu, Clemente, Della Corte, European Association for the Study of the Liver, Evans, Fang, Fattovich, Fontana, Fung, Gish, Hadziyannis, Halperin, Hann, Heathcote, Hongthanakorn, Hoofnagle, Hu, Huang, Hung, Hyun, Iino, Iloeje, Jeng, Keeffe, Kim, Komatsu, Konstantinou, Kowdley, Kuo, Kwong, Lai, Lai, Lai, Lai, Lampertico, Lau, Lau, Lee, Lee, Liang, Liaw, Liaw, Liaw, Liew, Lin, Lin, Lin, Liu, Liu, Liu, Lok, Lok, Lok, Loomba, MacLachlan, Manegold, Marcellin, Marcellin, Marcellin, Marcellin, Marcellin, Marcellin, Martin, Martin-Carbonero, Mast, McClune, McMahon, Mitchell, Monte, Murata, Mutimer, Nafa, Nguyen, Nguyen, Nikolopoulos, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Papatheodoridis, Park, Park, Park, Patterson, Perrillo, Perrillo, Pollack, Prati, Qiu, Reijnders, Sarin, Seto, Seto, Sherman, Shim, Shiraki, Sinatra, Sinn, Soriano, Stevens, Takano, Takayama, Takkenberg, Terrault, Thibault, Thio, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tse, Wang, Wedemeyer, Wei, Wen, Wiseman, Wursthorn, Xie, Xu, Yi, Yi, Yu, Yu, Yuen, Yuen, Yuen, Yuen, Yuen, Zhang, Zhang, Zhang, Zou   +173 more
core   +2 more sources

Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg

Scientific Reports, 2020
Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) for its assembly and release. Current HBV treatments are only marginally effective against HDV because they fail to inhibit HBsAg production/secretion.
L. Shekhtman, S. Cotler, L. Hershkovich, S. Uprichard, M. Bazinet, V. Pantea, V. Cebotarescu, Lilia Cojuhari, P. Jimbei, A. Krawczyk, U. Dittmer, A. Vaillant, H. Dahari   +12 more
semanticscholar   +1 more source

Evidence for the stress-linked immunocompetence handicap hypothesis in humans [PDF]

, 2012
Secondary sexual traits that develop under the action of testosterone, such as masculine human male facial characteristics, have been proposed to signal the strength of the immune system due to the sex hormone's immunosuppressive action.
Kecko, Sanita, Kivleniece, Inese, Krama, Tatjana, Krams, Indrikis, Moore, Fhionna R., Rantala, Markus J., Skrinda, Ilona   +6 more
core   +4 more sources

Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections [PDF]

, 2021
Background. Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside analogues (NAs) is life-long and reduces but does not eliminate the risk of cancer.
Ahlén, G, Frelin, L, Jagya, N, Johansson, M, Maravelia, P, Meuleman, Philip, Ni, Y, Pasetto, A, Pater, L, Pérez, NC, Sällberg, M, Urban, S, Verch, G, Verhoye, Lieven   +13 more
core   +1 more source